Publications by authors named "Poloko M Kebaabetswe"
Article Synopsis
- Recent clinical trials demonstrate that daily oral TDF/FTC pre-exposure prophylaxis (PrEP) significantly reduces the risk of HIV transmission.
- An analysis of 53 interviews from the TDF2 study in Botswana helps identify participant perspectives on retention and adherence to PrEP.
- Key factors for improving participant retention and adherence include pre-enrollment education, clear communication of obligations and side effects, understanding non-adherence impacts, and fostering external social support.
Background: Concurrent with efforts to establish national and regional biorepositories in Africa is widespread endorsement of ethics committees as stewards of the interests of individual donors and their communities. To date, ethics training programs for IRB members in Botswana have focused on ethical principles and international guidelines rather than on the ethical dimensions of specific medical technologies and research methodologies. Little is known about the knowledge and concerns of current and prospective IRB members in Botswana with respect to export, reuse, storage, and benefit-sharing of biospecimens.
View Article and Find Full Text PDFArticle Synopsis
- - The study on product adherence in Botswana's oral pre-exposure prophylaxis trial found that among 1,219 participants, the adherence rate was high at 94% based on both pill counts and self-reports.
- - Key factors influencing adherence included adverse events like nausea and concerns about side effects, with self-reported adherence linked to having an HIV-positive partner and living in Francistown.
- - Main barriers to adherence were refill delays and logistical issues, while the use of cellphone alarms was identified as an effective strategy to improve adherence.
Background: Preexposure prophylaxis with antiretroviral agents has been shown to reduce the transmission of human immunodeficiency virus (HIV) among men who have sex with men; however, the efficacy among heterosexuals is uncertain.
Methods: We randomly assigned HIV-seronegative men and women to receive either tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or matching placebo once daily. Monthly study visits were scheduled, and participants received a comprehensive package of prevention services, including HIV testing, counseling on adherence to medication, management of sexually transmitted infections, monitoring for adverse events, and individualized counseling on risk reduction; bone mineral density testing was performed semiannually in a subgroup of participants.